Luis
Pérez de Llano
![Foto de Luis](/img/nophoto.png)
![Foto de Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias](/img/noimage_org.png)
Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias
Madrid, EspañaPublicacións en colaboración con investigadores/as de Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (20)
2024
-
Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia
Scientific reports, Vol. 14, Núm. 1, pp. 12726
2023
-
First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma
Journal of Investigational Allergology and Clinical Immunology
-
Redefining the Role of Bronchoscopy in the Workup of Severe Uncontrolled Asthma in the Era of Biologics: A Prospective Study
Chest, Vol. 164, Núm. 4, pp. 837-845
-
Response to Monoclonal Antibodies in Asthma: Definitions, Potential Reasons for Failure, and Therapeutic Options for Suboptimal Response
Journal of investigational allergology & clinical immunology, Vol. 33, Núm. 1, pp. 1-13
2022
-
Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis
Archivos de Bronconeumologia, Vol. 58, Núm. 3, pp. 281-283
-
Early Recognition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria
Chest, Vol. 162, Núm. 4, pp. 768-781
2021
-
Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 7, pp. 2725-2731
2020
-
Hospital epidemics tracker (hepitracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers
JMIR Public Health and Surveillance, Vol. 6, Núm. 3
-
Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab
Allergy: European Journal of Allergy and Clinical Immunology
2019
-
A Simple Score for Future Risk Prediction in Patients with Controlled Asthma Who Undergo a Guidelines-Based Step-Down Strategy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 4, pp. 1214-1221.e3
-
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 7, pp. 2277-2283.e2
2018
-
Accuracy of a New Algorithm to Identify Asthma–COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease
Archivos de Bronconeumologia, Vol. 54, Núm. 4, pp. 198-204
-
Cardiovascular Studies in Patients with Chronic Obstructive Pulmonary Disease Due to Biomass Smoke or Tobacco
Lung, Vol. 196, Núm. 2, pp. 195-200
-
Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: A network approach
International Journal of COPD, Vol. 13, pp. 591-601
-
The Role of FENO in the Diagnosis and Control of Asthma. Expert Multidisciplinary Group Debate during the Asthma Meeting Point 2017
Archivos de Bronconeumologia
-
The post-truth behind the asthma-COPD overlap and the orbit of Mercury: lessons from the CHACOS study
Archivos de Bronconeumologia, Vol. 54, Núm. 4, pp. 175-176
2017
-
Asthma-COPD overlap is not a homogeneous disorder: Further supporting data
Respiratory Research
2016
-
Asthma, Chronic Obstructive Pulmonay Disease and Other Combinations
Archivos de Bronconeumologia, Vol. 52, Núm. 10, pp. 499-500
-
Validation of the 'Test of the Adherence to Inhalers' (TAI) for Asthma and COPD Patients
Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 29, Núm. 2, pp. 142-152
2012
-
Omalizumab therapy in severe asthma: Experience from the Spanish registry - Some new approaches
Journal of Asthma, Vol. 49, Núm. 4, pp. 416-422